LEGO Linkers for ADCs
How to design more stable and predictable antibody-drug conjugates
Maryam Mahdi | | Quick Read
Antibody-drug conjugates (ADCs) couple the potency of a cytotoxic agent with the selectivity of an antibody. But despite early promise of the technology, only five ADCs have received market approval to date (we explored the potential of ADCs to move to the forefront of the targeted therapy space here). In an effort to develop more stable and predictable ADCs, an investigational team based at the Brigham and Women’s Hospital in Boston, US, has been using computational simulations to focus on improving a crucial element: the linker (1).
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine